Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16566110 | 0.86 | IDO1 (0.46) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL11027115 | 0.84 | CACNB4 (0.55) | IDO1MAPT | |
| SCHEMBL11029123 | 0.84 | MAPT (0.45) | IDO1GSK3BMAPT | |
| SCHEMBL16566268 | 0.82 | IDO1 (0.44) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL7375443 | 0.81 | MAPT (0.49) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL18552441 | 0.81 | MAPT (0.49) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL824370 | 0.80 | IDO1 (0.45) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL23567209 | 0.80 | BRPF1 (0.41) | IDO1GSK3BBRPF1CREBBPMAPT | |
| SCHEMBL9899341 | 0.80 | IDO1 (0.45) | IDO1GSK3BBRPF1CREBBPTDO2 | |
| SCHEMBL23785707 | 0.80 | IDO1 (0.41) | IDO1GSK3BBRPF1CREBBPTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025050122-A1 | MOLECULAR DESIGN OF ELECTROACTIVE SPECIES AND MATERIALS PROCESSING METHODS IN ORGANIC REDOX FLOW BATTERIES | BIOZEN BATTERIES, INC. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2025050122-A1 | MOLECULAR DESIGN OF ELECTROACTIVE SPECIES AND MATERIALS PROCESSING METHODS IN ORGANIC REDOX FLOW BATTERIES | BIOZEN BATTERIES, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-11007177-B2 | Compositions comprising a combination of a substituted flavonoid and a substituted indole for treating ocular diseases | UNIVERSITY OF MACAU (CN) | 2021-05-18 | — | — | US | disclosed |
| WO-2012078519-A2 | 3-ACYLIDENE-2-OXOINDOLE DERIVATIVES FOR INHIBITION OF TRANSGLUTAMINASE 2 | NUMERATE, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11007177-B2 | Compositions comprising a combination of a substituted flavonoid and a substituted indole for treating ocular diseases | IDO1, IDO2, SYVN1 | IDO1 1/4885GSK3B 1508/4885BRPF1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.